Clorox Co’s recently made public that its Officer Marriner Kirsten acquired Company’s shares for reported $1.25 million on Mar 10 ’25. In the deal valued at $152.35 per share,8,227 shares were bought.
Then, Hilt Angela C sold 1,248 shares, generating $206,622 in total proceeds. Upon selling the shares at $165.56, the EVP – Chief Legal Officer now owns 19,833 shares.
Before that, Hilt Angela C bought 1,248 shares. Clorox Co shares valued at $205,820 were divested by the Officer at a price of $164.92 per share.
Wells Fargo upgraded its Clorox Co [CLX] rating to an Equal weight from a an Underweight in a research note published recently. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in early November from “a Sell” to “a Hold”. Jefferies also remained covering CLX and has increased its forecast on October 01, 2024 with a “Buy” recommendation from previously “Hold” rating. TD Cowen started covering the stock on July 23, 2024. It rated CLX as “a Sell”.
Price Performance Review of CLX
On Tuesday, Clorox Co [NYSE:CLX] saw its stock jump 0.25% to $148.43. Over the last five days, the stock has lost -1.55%. Clorox Co shares have fallen nearly -8.61% since the year began. Nevertheless, the stocks have fallen -3.47% over the past one year. While a 52-week high of $171.37 was reached on 01/27/25, a 52-week low of $127.60 was recorded on 02/05/25. SMA at 50 days reached $155.50, while 200 days put it at $152.71.
Levels Of Support And Resistance For CLX Stock
The 24-hour chart illustrates a support level at 146.56, which if violated will result in even more drops to 144.69. On the upside, there is a resistance level at 150.18. A further resistance level may holdings at 151.93. The Relative Strength Index (RSI) on the 14-day chart is 42.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.21%. Stochastics %K at 20.63% indicates the stock is a holding.
The most recent change occurred on June 24, 2024 when Exane BNP Paribas began covering the stock and recommended ‘”an Underperform”‘ rating along with a $130 price target.
